1cGAS Expression is Enhanced in Systemic Sclerosis Associated Interstitial Lung2Disease and Stimulates Inflammatory Myofibroblast Activation

Sheeline Yu¹, Buqu Hu¹, Ying Sun¹, Xue Yan Peng¹, Chris J. Lee¹, Samuel Woo¹, John
McGovern¹, Jana Zielonka¹, Tina Saber¹, Alexander Ghincea¹, Shifa Gandhi¹, Anjali Walia¹,
Taylor Pivarnik¹, Genta Ishikawa¹, Shuai, Shao¹, Huanxing Sun¹, Baran Ilayda Gunes², Sophia
Kujawski², Stephanie Perez², William Odell², Monique Hinchcliff², John Varga³, Carol Feghali-

- 7 Bostwick⁴, Maor Sauler¹, Jose L. Gomez¹, *Changwan Ryu¹, *Erica L. Herzog^{1,5}
- ¹Yale School of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine
- ⁹ ²Yale School of Medicine, Department of Internal Medicine, Section of Rheumatology, Allergy,
- 10 and Immunology
- ³University of Michigan, Department of Internal Medicine, Division of Rheumatology
- ⁴Medical University of South Carolina, Department of Medicine
- 13 ⁵Yale School of Medicine, Department of Pathology
- ^{*}Equally contributed to this work
- 15

16 **Corresponding author**

- 17 Erica L. Herzog
- 18 Email: erica.herzog@yale.edu
- 19

20 Contributions

SY conducted the investigation, interpreted data, and wrote and edited the manuscript. BH, YS, 21 XYP, CJL, SW, JM, JZ, TS, AG, SG, AW, TP, SS, HS, MS, and JLG performed the investigation 22 23 and analyzed data. BIG, SK, SP, WO, and MH recruited subjects, performed the investigation, 24 and analyzed data. JV provided conceptualization, resources, supervision, and funding acquisition. CFB provided conceptualization and resources. CR and ELH provided 25 conceptualization, resources, supervision, project administration, funding acquisition, and wrote 26 27 and edited the manuscript. All authors participated in manuscript preparation and provided final 28 approval of the submitted work.

29

30 Funding

31 JZ was supported by T32HL007778. AG was supported by T32HL007778. GI was supported by a Scholar Award from the Pulmonary Fibrosis Foundation, Wit Family Distinguished Scholar in 32 Inflammation Science, and Yale Physician Scientist Development Award. MH was supported by 33 34 R01 AR073270. JG was supported by R01HL153604 and R03 HL154275. CR was supported by 35 K08HL151970-01 and Boehringer-Ingelheim Discovery Award. ELH was supported by 5R01HL163984-02 and 5R01HL152677-04. The content is solely the responsibility of the 36 authors and does not necessarily represent the official views of the National Institutes of Health 37 38 or other funding sources.

39

40 Word Count:

- 41 3609 words
- 42

43 **TAKE HOME MESSAGE**

Using various translational models of SSc-ILD, we found that activation of the innate immune receptor cGAS contributes to inflammatory myofibroblast phenotypes that are attenuated by inhibiting this receptor.

47

48 **ABSTRACT**

Objective: The lungs of patients with Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) contain inflammatory myofibroblasts arising in association with fibrotic stimuli and perturbed innate immunity. The innate immune DNA binding receptor Cyclic GMP-AMP synthase (cGAS) is implicated in inflammation and fibrosis, but its involvement in SSc-ILD remains unknown. We examined cGAS expression, activity, and therapeutic potential in SSc-ILD using cultured fibroblasts, precision cut lung slices (PCLS), and a well-accepted animal model.

56 **Methods:** Expression and localization of cGAS, cytokines, and type 1 interferons were 57 evaluated in SSc-ILD lung tissues, bronchoalveolar lavage (BAL), and isolated lung fibroblasts. 58 *CGAS* activation was assessed in a publicly available SSc-ILD single cell RNA sequencing 59 dataset. Production of cytokines, type 1 interferons, and α SMA elicited by TGF β 1 or local 50 substrate stiffness were measured in normal human lung fibroblasts (NHLFs) via qRT-PCR, 51 ELISA, and immunofluorescence. Small molecule cGAS inhibition was tested in cultured 52 fibroblasts, human PCLS, and the bleomycin pulmonary fibrosis model.

Results: SSc-ILD lung tissue and BAL are enriched for cGAS, cytokines, and type 1 interferons. The cGAS pathway shows constitutive activation in SSc-ILD fibroblasts and is inducible in NHLFs by TGF β 1 or mechanical stimuli. In these settings, and in human PCLS, cGAS expression is paralleled by the production of cytokines, type 1 interferons, and α SMA that are mitigated by a small molecule cGAS inhibitor. These findings are recapitulated in the bleomycin mouse model.

69 **Conclusion:** cGAS signaling contributes to pathogenic inflammatory myofibroblast phenotypes 70 in SSc-ILD. Inhibiting cGAS or its downstream effectors represents a novel therapeutic 71 approach.

- 72 Word Count: 250 words
- 73

74 **Key Words:** (1) Systemic Sclerosis; (2) Interstitial Lung Disease; (3) cGAS; (4) inflammatory

- 75 myofibroblast
- 76

77 INTRODUCTION

78 Systemic Sclerosis (SSc) is an autoimmune condition characterized by progressive 79 fibrosis of the skin and visceral organs [1]. Patients with SSc frequently develop interstitial lung 80 disease (SSc-ILD), a pulmonary condition characterized by inflammatory cell infiltration and 81 fibrotic remodeling [2]. SSc-ILD underlies the considerable morbidity and mortality in patients 82 with SSc [3], and current consensus treatment guidelines recommend immunosuppressive 83 agents and anti-fibrotic drugs that are not universally effective and impose significant burden in terms of side effects and cost [4-6]. Thus, understanding the mechanisms contributing to both 84 85 inflammation and fibrosis is imperative for the development of effective treatments to improve 86 patient care.

87 The lungs of patients with SSc-ILD exhibit varying degrees of immune activation and 88 extracellular matrix (ECM) accumulation [2]. Additionally, the lungs contain heterogeneous 89 fibroblast populations that produce inflammatory mediators, secrete collagens and other ECM 90 molecules, and express myofibroblast markers such as alpha smooth muscle actin (aSMA) [7-91 9]. These properties are inducible in normal human lung fibroblasts (NHLFs) by fibrotic stimuli, 92 including transforming growth factor beta 1 (TGF β 1) [10] and interactions with stiffened tissue 93 substrates [11]. The presence of inflammatory myofibroblasts in SSc-ILD may account for 94 heterogeneous treatment responses as currently used first-line treatments are designed to 95 either suppress the inflammatory function of immune cells or the fibrogenic function of 96 fibroblasts. Missing from our therapeutic strategies are agents that can simultaneously mitigate 97 inflammation and fibrogenesis in a single population of fibroblast effector cells. In view of these limitations, the identification of druggable pathways that simultaneously contribute to 98 99 inflammatory responses and fibrotic functions in fibroblasts remains a critical unmet need.

100 Innate immune drivers of fibroblast activation have emerged as important pathogenic 101 pathways in SSc-ILD. Of particular interest are nucleic acid receptors that recognize and

102 respond to DNA and RNA derived from invading pathogens and injured cells. We and others 103 have demonstrated vital roles for Toll-like receptor 9 in fibroblast activation and disease progression in SSc-ILD and associated conditions [11-13]. In contrast, the pathogenic 104 105 contribution of alternate nucleic acid receptors, such as cyclic guanosine monophosphate-106 adenosine monophosphate synthase (cGAS), remains less well understood. The broadly expressed intracellular receptor cGAS is a nucleotidyltransferase that, upon binding to cytosolic 107 108 DNA derived from invading pathogens or endogenous sources (nuclei, mitochondria), catalyzes the production of 2,3-cGAMP [14]. This substrate then activates the cytosolic kinase stimulator 109 110 of interferon genes (STING) to initiate production of interferon regulatory factor-3 (IRF3) and 111 nuclear factor-kB (NFkB) dependent proinflammatory cytokines, chemokines, and type I 112 interferons in immune cells [15]. Reflecting the emerging importance of cGAS in disease 113 development, numerous approaches to cGAS-STING modulation exist in the therapeutic 114 pipeline for conditions of chronic inflammation and autoimmunity [15, 16]. Intriguingly, the 115 cGAS-STING pathway has also been implicated as a fibroblast activator in diverse conditions such as cancer [17], aging [18], pulmonary fibrosis [19], and SSc [20]; and endogenous cGAS 116 117 ligands such as DNA from mitochondria (mtDNA) and nuclear sources are elevated in patients 118 with SSc [12, 13, 20]. However, the mechanistic and therapeutic potential of cGAS in SSc-ILD is 119 currently unknown.

On the basis of this biology, we surmised that engagement of cGAS drives inflammatory myofibroblast accumulation in SSc-ILD. To test this hypothesis, we evaluated the expression and function of cGAS in patient samples, *ex vivo* modeling systems, and in a well-accepted mouse model. Our results show that expression of cGAS and its associated inflammatory mediators is increased in lung tissue and bronchoalveolar lavage (BAL) fluid from SSc-ILD patients, where it is constitutively expressed and activated in SSc-ILD fibroblasts, and inducible in NHLFs following stimulation with either TGFβ1 or mechanical stimuli. In these settings, and in

human precision cut lung slices (PCLS), cGAS expression is paralleled by production of inflammatory mediators and α SMA expression that are mitigated by a small molecule cGAS inhibitor. Similar anti-fibrotic effects of cGAS inhibition are seen in an experimental model of mouse lung fibrosis. Altogether, our compelling results implicate cGAS in inflammatory fibroblast activation and fibrosis underlying SSc-ILD pathogenesis, putting forth cGAS inhibition as a novel therapeutic in this disease.

133

134 MATERIALS AND METHODS

135 Detailed methods are provided in the online supplement.

136

137 Human Subjects

De-identified lung tissues and primary lung fibroblasts that had been previously obtained at the University of Pittsburgh (IRB 970946), and de-identified BAL fluid specimens that had been previously collected from healthy donors and patients with SSc using informed consent on protocols approved by Institutional Review Board at the Yale School of Medicine (HIC 2000024862), were used in this study.

143 Single Cell RNA Sequencing (scRNA seq) Analysis

Analyses of scRNA seq data (GSE128169) were performed with Seurat version 5.0.318 as described in the online supplement. To identify cell types expressing genes associated with cGAS, the AddModuleScore, a Seurat function that calculates the gene expression level of a cluster of genes on a single cell level and then subtracts the aggregated expression of a randomly assigned control set, was used.

149 **Fibroblast Cultures**

Fibroblasts harvested from the lungs of patients with SSc-ILD were cultured in the absence or presence of the small molecule cGAS inhibitor G140 (10 μ M, Invivogen). NHLFs were cultured in the absence or presence of recombinant human TGF β 1 (5 ng/ml) and CpG ODN2006 (50 μ mol) and in the absence or presence of G140. In parallel, NHLFs were cultured on collagencoated hydrogels (Matrigen) of 1 kPA and 25 kPA stiffness in the absence or presence of G140.

155 Human PCLS

PCLS from normal human donors (Institute for In Vitro Sciences) were incubated in culture media supplemented with or without an inflammatory fibrotic cocktail (IFC) comprised of the following: TGF β 1 (5 ng/ml), platelet-derived growth factor-AB (PDGF-AB, 5 μ M), tumor necrosis factor alpha (TNF- α , 10 ng/ml), lysophosphatidic acid (LPA, 5 μ M), and CpG ODN2006 (50 μ mol); PCLS subjected to this cocktail were then treated in the absence or presence of G140 (10 nM).

162 Mouse Experiments

Animal procedures were approved by the Yale Institutional Animal Care and Use Committee. C57Bl/6 mice received a single dose of inhaled bleomycin (0.8 units/kg) or normal saline. Vehicle control or G140 (30 mg/kg) was administered via intraperitoneal injection on days 3, 7, and 10 post-bleomycin. Mice were euthanized on day 14 and biospecimens were collected for analysis.

168 **RNA Isolation and qRT-PCR**

Total cellular RNA was isolated and reverse transcribed for *GAPDH*, *ACTA2*, and *CGAS* from
biospecimens as described in the online supplement.

171 Cell Lysis

172 Cells were washed and lysed in a solution containing Pierce RIPA buffer and a Halt[™] Protease
173 Inhibitor Cocktail (ThermoFisher).

174 **Quantification of Cytokines**

Multiplex quantification of interleukin-6 (IL-6), interleukin 1-beta (IL-1β), tumor necrosis factor
alpha (TNF-α), monocyte chemoattractant protein-1 (MCP-1), interferon-gamma inducible
protein-10 (IP-10), interferon alpha (IFN-α), and interferon beta (IFN-β) using the U-PLEX
Cytokine Panel Human Kit or U-Plex Cytokine Panel Mouse Kit (Mesoscale Discovery).

179 **ELISA**

Cell lysates were assayed for αSMA (Abcam) or cGAS (Cell Signaling Technology) via
 commercially available ELISA as described in the online supplement.

182 MTT Assay

183 Cell viability was determined using MTT assays (Thermofisher) as described in the online184 supplement.

185 cGAS Immunohistochemistry (IHC)

Formalin fixed, paraffin embedded slides of human lung tissue from healthy or SSc-ILD donors (n=4/each) were stained with a human cGAS antibody (1:100, Invitrogen) as described in the online supplement. cGAS quantification was performed by manually counting total nuclei and nuclei from cGAS-expressing cells; results were reported as the percentage of positive cGAS cells per high-power field.

191 Immunofluorescence (IF)

192 IF detection of α SMA and cGAS in fibroblasts were performed with mouse anti- α SMA (1:250, 193 Abcam) and rabbit monoclonal cGAS (1:100, Invitrogen) antibodies as described in the online 194 supplement.

195 Lung Histology

Formalin fixed, paraffin embedded lung sections from PCLS or mouse lungs were stained with Masson's trichrome [21]. Collagen was quantified with ImageJ software as described in the online supplement. Soluble collagen was quantified using the Sircol Collagen Assay kit (Biocolor) [22].

200 Bulk RNA Sequencing

RNA isolated from PCLS was sequenced on the Illumina NovaSeq platform as described in the
online supplement. Differential gene expression was identified with the DESeq2 package on R
statistical software (version 4.3.2). Heatmaps were generated in R with the gplots package.
Pathway enrichment analysis was conducted via MetaCore; a false discovery rate (FDR) < 0.10
was considered significant.

206 Statistical Analysis

Data distribution was assessed using Shapiro-Wilk test, and categorical data was analyzed with Fisher's exact test using GraphPad Prism 9.4.1. Multiple hypothesis testing was conducted with one-way ANOVA with Bonferroni correction with GraphPad Prism. Pairwise comparisons were conducted with an unpaired t-test or Mann Whitney test based on data distribution with GraphPad Prism. p-values < 0.05 were considered significant.

212

213 **RESULTS**

Expression of cGAS and its associated soluble mediators are enriched in the lungs of patients with SSc-ILD

216 To assess a potential relationship between cGAS and SSc-ILD, IHC was performed on lung 217 tissues obtained from control (unsuitable organ donors) or SSc-ILD patients undergoing 218 orthotopic lung transplantation. In contrast to the low level of cGAS detection observed in 219 control samples, SSc-ILD lung tissues displayed abundant cGAS expression in cells exhibiting 220 the morphology of immune populations, epithelium, and fibroblasts (Figures 1A,B). cGASassociated soluble mediators were then measured in BAL specimens from control and SSc 221 222 donors shown in Table 1. Compared to healthy controls, SSc-ILD BAL showed high 223 concentrations of cytokines (IL-6, IL-1 β , TNF- α , Figures 1C-E), chemokines (MCP-1, IP-10, 224 Figures 1F,G), and type 1 interferons (IFN- α , IFN- β , Figures 1H,I) all of which are known to be 225 downstream of cGAS activation. These data show that the lungs of patients with SSc-ILD show 226 strong expression of cGAS and its associated soluble mediators.

227 Enhanced expression and activation of cGAS in SSc-ILD fibroblasts

228 Having identified enhanced cGAS expression in SSc-ILD lung tissues, we then investigated this 229 biology in disease-relevant cell types. We began by analyzing a publicly available scRNA seg 230 dataset (GSE128169) generated from end-stage SSc-ILD lung explants. Consistent with our 231 IHC findings above, multiple cell populations showed transcriptional evidence of cGAS 232 activation (Figures S1 and 2A). When this analysis was limited to stromal cells, fibroblasts 233 exhibited high expression of cGAS pathway transcripts (Figure 2B). These in silico studies were 234 confirmed in vitro with primary lung fibroblasts, where evaluation of cGAS expression via gRT-235 PCR and ELISA showed increased expression at the mRNA and protein levels (Figures 2C,D). 236 Moreover, IF analysis revealed that the baseline nuclear cGAS localization seen in NHLFs was 237 accompanied by the detection of cytoplasmic aggregates in SSc-ILD fibroblasts, indicating that 238 these cells may exist in a state of heightened cGAS activation (Figures S2 and 2E). Importantly,

this phenotype was accompanied by increased production of cGAS-associated inflammatory mediators (IL-6, IL-1 β , TNF- α , MCP-1, IP-10, IFN- α , IFN- β) along with elevated mRNA and protein levels of the myofibroblast marker α SMA (Figures 3A-I). These results implicate cGAS as a driver of inflammatory myofibroblast activation in SSc-ILD.

A small molecule cGAS inhibitor mitigates inflammatory mediator production and fibrotic

244 activation of SSc-ILD fibroblasts

245 To link cGAS more firmly with inflammatory myofibroblast activation in SSc-ILD, we performed 246 loss of function studies using the cGAS inhibitor G140. This commercially available, highly specific small molecule inhibitor blocks DNA entry into human cGAS catalytic pocket to impede 247 248 enzymatic activation [23]. In our study, treatment of SSc-ILD fibroblasts with G140 reduced 249 cytoplasmic cGAS aggregates (Figure 4A), suggesting successful inhibition. This observation 250 was paralleled by decreased production of inflammatory mediators (IL-6, IL-1 β , TNF- α , MCP-1, 251 IP-10, IFN- α , and IFN- β , Figures 4B-H). G140 treatment also reduced α SMA mRNA measured 252 by gRT-PCR (Figure 4I) and protein measured by IF and ELISA (Figures 4A,J). Importantly, 253 these findings were not due to alterations in cellular viability as the results of an MTT assay 254 were similar between untreated and treated cells (Figure 4K). These studies show that cGAS 255 inhibition reduces production of cytokines, chemokines, type 1 interferons, and aSMA expression in SSc-ILD fibroblasts, providing proof of concept evidence for targeting cGAS in this 256 257 disease.

Small molecule cGAS inhibition suppresses TGFβ1 and CpG induced fibroblast activation

Studies of diseased lung fibroblasts are useful for the development of mechanistic-based SSc-ILD therapies. However, while providing evidence of target engagement, they are limited by the end-stage nature of the disease. Because the therapeutic goal is to prevent clinical progression,

263 studies aimed at preventing cellular activation have the potential to halt or even reverse 264 disease. Reasoning that fibroblasts adopt their ultimate phenotype in response to 265 microenvironmental cues, we developed a model of cGAS activation in which NHLFs were co-266 stimulated with TGFB1 and CpG ODN2006 to simulate the endogenous cGAS ligand mtDNA 267 (Figures S3A,B). Following co-stimulation, NHLFs phenocopied many aspects of SSc-ILD fibroblasts, including increased expression and cytoplasmic aggregation of cGAS (Figures S4A-268 269 C), production of inflammatory mediators (IL-6, IL-1β, TNF-α, MCP-1, IP-10, IFN-α, IFN-β, 270 Figures S4D-J), and αSMA mRNA and protein (Figures S4K,L). These changes were cGASdependent as treatment with G140 diminished cytoplasmic cGAS aggregation (Figure 5A) and 271 272 suppressed production of all inflammatory mediators except for IL-6 (Figures 5B-H). Production 273 of αSMA mRNA and protein were also reduced (Figures 5I,J). Lastly, a MTT assay revealed 274 these findings to be unrelated to changes in cell viability (Figure 5K). Taken together, these data 275 provide evidence of cGAS antagonism as a novel strategy of mitigating the fibroblast activation 276 that arises in response to TGF^{β1} and endogenous cGAS ligands.

277 A small molecule cGAS inhibitor opposes stiffness-induced fibroblast activation

278 Cells encounter and respond to physical properties, such as stiffness, in their microenvironment. 279 While cGAS has been previously linked to fibrotic mechanosensing [18], its involvement in SSc-280 ILD and therapeutic targeting in lung fibroblasts remains underexplored. Thus, we investigated 281 this area using tunable hydrogels constructed to simulate the stiffness of normal (1 kPA) or SSc-282 ILD (25 kPA) lung [24]. Compared to cells cultured under physiologic conditions, NHLFs grown 283 on 25 kPA gels developed increased cGAS mRNA transcription and protein levels (Figures 284 S5A,B), secretion of IL-1 β , MCP-1, IP-10, IFN- α , and IFN- β , but not IL-6 or TNF- α (Figures S5C-I) as well as induction of αSMA mRNA and protein expression (Figures S5J,K). Treatment 285 with G140 reduced IL-1 β , IP-10, IFN- α , and IFN- β , but not MCP-1 (Figures 6A-E), and 286 287 attenuated aSMA mRNA and protein (Figures 6F,G) without affecting cellular viability (Figure

6H). Overall, these data frame cGAS as a druggable driver of mechanosensitive fibroblast
responses that are pathogenic in SSc-ILD.

A small molecule cGAS inhibitor suppresses inflammatory mediator production and fibrotic endpoints in human PCLS

Studies of isolated lung fibroblasts provide direct evidence of cell autonomous responses in 292 293 these fibrotic cells. However, they are limited by the lack of information regarding the complex 294 multicellularity of the adult lung, which can activate fibroblasts via non-cell autonomous processes. To overcome these issues, we extended our studies to include PCLS, an advanced 295 296 in vitro modeling system that allows previously impossible tissue level insights into human lung 297 injury, repair, and remodeling. This technology improves upon standard primary monoculture 298 methods by replicating the complex 3D topography and multicellularity of the lung [25]. Our 299 preliminary studies used a model of normal PCLS cultured in media containing an inflammatory 300 fibrotic cocktail (IFC) of TGF β , PDGF-AB, TNF- α , and LPA, and supplemented with the mtDNA surrogate CpG ODN2006. As compared to naïve PCLS, those cultured in this IFC displayed 301 302 enhanced collagen content (Figures S6A-B), cGAS transcripts (Figure S6C), protein levels of IL-6, IL-1 β , TNF- α , MCP-1, IP-10, and IFN- α , but not IFN- β (Figures S6D-J). α SMA transcripts 303 304 were also increased (Figure S5K). Treatment with the cGAS inhibitor G140 reduced all these 305 endpoints (Figures 7A-I). Lastly, to identify parallel transcriptional changes that occur in the 306 absence or presence of G140, we conducted exploratory bulk RNA sequencing and identified 307 126 differentially expressed genes (Figure 7J). Unbiased pathway enrichment analysis revealed 308 a multitude of transcriptional changes involving inflammatory and immune function with the most 309 highly altered pathways being related to cytoskeletal remodeling, IL-17, cell adhesion, antigen 310 presentation, NF-kB activation, interferon beta signaling, and mesenchymal cell activation 311 (Figure 7K). The finding that cGAS inhibition suppresses production of cytokines, chemokines, 312 type 1 interferons, αSMA expression, and collagen production during human lung fibrogenesis

suggests that targeting cGAS and/or its associated pathways holds therapeutic potential in SSc-ILD.

315 A small molecule cGAS inhibitor mitigates bleomycin-induced pulmonary fibrosis

316 Finally, having demonstrated the benefit of a cGAS inhibitor in orthogonal ex vivo modeling experiments, we sought to determine its efficacy in vivo. For this purpose, we used the 317 318 bleomycin model of fibrosis in mice, which is the most widely accepted SSc-ILD animal model 319 [2]. Mice were subjected to orotracheal instillation of either normal saline or bleomycin in 320 presence of vehicle or G140. As shown in Figures S7A-C, bleomycin challenged mice exhibited 321 greater lung collagen accumulation than those that received normal saline or G140 alone. Evaluation of BAL fluid revealed elevations of IL-6, IL-1 β , TNF- α , MCP-1, IP-10, IFN- α , and IFN-322 β (Figures S7D-J). When bleomycin-challenged mice were treated with G140, we observed 323 marked reductions in lung collagen content (Figures 8A-C) and BAL concentrations of IL-6, 324 325 TNF- α , IP-10, IFN- α , and IFN- β , but not IL-1 β and MCP-1 (Figures 8D-J). When viewed in combination, our results identify cGAS as a modulator of inflammatory fibroblast activation in 326 327 mammalian lung fibrosis and supports the clinical development of cGAS inhibitors for treatment 328 of SSc-ILD.

329

330 **DISCUSSION**

Innate immunity and inflammatory myofibroblast activation are increasingly linked to SSc-ILD; however, their mechanistic and therapeutic implications are not well understood [26]. Here we identified the cytosolic DNA sensor cGAS as a mechanistic driver of and therapeutic target in SSc-ILD. Our results revealed that expression of cGAS and its downstream mediators are enhanced in SSc-ILD lung tissues, BAL fluid, and lesional fibroblasts. These findings are recapitulated in SSc-ILD modeling systems, including NHLFs exposed to biochemical and

biophysical fibrotic stimuli, human PCLS exposed to fibrogenic mediators, and the well accepted
bleomycin mouse model. A small molecule cGAS inhibitor exerted an anti-inflammatory and
antifibrotic effects in all these settings. Targeting aberrant cGAS activation holds promise as an
innovative strategy in SSc-ILD, as well for myriad other inflammatory fibrosing conditions
characterized by autoimmunity [27], neurodegeneration [28], cancer [17], and aging [18].

Upon its 2013 discovery, cGAS was described as a nucleotidyltransferase that 342 343 recognizes pathogen-derived DNA and activates type 1 interferon production in a STINGdependent, IRF3 dependent manner [14]. Since this time, cGAS has been shown to be 344 345 activated by endogenous DNA, including that derived from nuclei and mitochondria [10]. cGAS 346 can recognize self-ligands that leak into the cytoplasm following DNA damage responses or 347 mitochondrial stress, or that which have been internalized as damage associated molecular 348 patterns (DAMPS) present in the extracellular milieu. Our prior work implicated mtDNA as a 349 putative cGAS activator [10] and the present study advances this notion as we were able to 350 induce fibroblast activation and cGAS signaling with the administration of exogenous CpG, a 351 surrogate for cell-free mtDNA. Further work characterizing the nature of mtDNA and its 352 interactions with cGAS has the potential to elucidate intervenable innate immune mechanisms 353 of inflammatory fibroblast activation in SSc-ILD.

354 The results reported herein are predicated on the ability of cGAS to activate STING and 355 induce NFkB and IRF3 signaling [14]. In our work, cGAS inhibition suggested context dependent aspects of the various modeling systems. For example, while SSc-ILD BAL and 356 357 fibroblasts are enriched for NFkB-dependent and IRF3-dependent cytokines and type 1 358 interferons, we have not characterized the contribution of STING and its associated transcription 359 factors in our work. The expression of NFkB and IRF3 dependent inflammatory mediators supports pleiotropic effect, and the effect on α SMA expression likely reflects the recently 360 described role of cGAS-STING in canonical TGF^β1 activation and YAP/TAZ mediated 361

mechanosensing. It is equally possible, however, that our observations stem from noncanonical cGAS pathways, such as PERK, that are independent of STING. Further study is needed to decipher the context-dependent paradigm of cGAS activation and its downstream signaling pathways in SSc-ILD and related conditions.

366 In terms of therapeutic potential, cGAS inhibition remains an active area of investigation 367 for clinical benefit. Currently available antagonists include the anti-malarial agents hydroxychloroguine and guinacrine, which bind to the minor groove of the DNA-cGAS interface 368 to disrupt ligand-receptor interactions [29]. Suramin, a drug indicated for the treatment of river 369 370 blindness and African sleeping sickness, acts as a DNA mimic that competitively binds to cGAS 371 and inhibits 2,3,-cGAMP synthesis [30]. While repurposing these agents for SSc-ILD is a consideration, the potential for non-specific, off-target effects limits their widespread use [31, 372 373 32]. Thus, the identification of compounds that directly inhibit cGAS has been actively pursued. 374 One promising compound was RU.521, which occupies the catalytic site of cGAS to inhibit generation of 2,3,-cGAMP [31]. However, this effect was only seen in mouse studies, propelling 375 376 the development of G140, a human-specific small molecule inhibitor of cGAS with a mechanism of action similar to RU.521 [23]. Moreover, relative to similar compounds, G140 demonstrated 377 378 superior efficacy inhibiting production of various lipopolysaccharide-induced cytokines in mouse 379 lung injury models [32]. Our study is the first to evaluate G140 in this inflammatory fibrotic 380 setting, and further work is needed for testing this agent in SSc-ILD human cohorts.

While novel and thought-provoking, our findings raise additional questions for future research. Although we have identified fibroblasts as one site of activated cGAS function, additional cell types are likely involved. Mechanistically, we have not determined if cGAS activation mediates canonical versus non-canonical TGF β activation, nor its interactions with mechanosensitive signaling, such as those involving Hippo [33], YAP [34], FAK [34], and Rho associated kinase [35]. In terms of the cGAS ligand, we have not determined the contribution of

387 DNA derived from mitochondrial, nuclear, or even microbial sources. Moreover, we have yet to 388 determine the impact of canonical cGAS signaling components, such as the second messenger protein 2,3,-cGAMP and STING. Lastly, we have not evaluated how cGAS inhibition compares 389 390 to immunosuppressive strategies [5] and anti-fibrotic agents [36] that are currently in use. 391 Despite these relatively minor limitations, in the first of its kind study, we found that cGAS is 392 expressed in SSc-ILD lung tissues and that its inhibition mitigates the development of 393 inflammatory fibrosis in cellular, tissue-based, and animal models. Further investigation may 394 yield the development of cGAS targeted therapies for SSc-ILD and related conditions.

395

396 ACKNOWLEDGMENTS

To all of our patients with scleroderma: the authors commend your bravery and resilience in combatting this relentless disease. We hope and encourage you all to live your best lives.

400 **REFERENCES**

- Denton, C.P. and D. Khanna, *Systemic sclerosis*. Lancet, 2017. **390**(10103): p.
 1685-1699.
- 403 2. Herzog, E.L., et al., *Review: interstitial lung disease associated with systemic*404 *sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?* Arthritis
 405 Rheumatol, 2014. **66**(8): p. 1967-78.
- 3. Steen, V.D. and T.A. Medsger, *Changes in causes of death in systemic sclerosis, 1972-2002.* Ann Rheum Dis, 2007. 66(7): p. 940-4.
- 4. Rahaghi, F.F., et al., *Expert consensus on the management of systemic*409 *sclerosis-associated interstitial lung disease.* Respiratory Research, 2023. 24(1):
 410 p. 6.
- 5. Raghu, G., et al., *Treatment of Systemic Sclerosis–associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.* American Journal of Respiratory and Critical
 Care Medicine, 2023. 209(2): p. 137-152.
- 415 6. Johnson, S.R., et al., 2023 American College of Rheumatology (ACR)/American
 416 College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial
 417 Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
 418 Arthritis & Rheumatology, 2024. **76**(8): p. 1182-1200.
- Valenzi, E., et al., Single-cell analysis reveals fibroblast heterogeneity and
 myofibroblasts in systemic sclerosis-associated interstitial lung disease. Ann
 Rheum Dis, 2019. **78**(10): p. 1379-1387.
- Reyfman, P.A., et al., Single-Cell Transcriptomic Analysis of Human Lung *Provides Insights into the Pathobiology of Pulmonary Fibrosis.* Am J Respir Crit
 Care Med, 2019. **199**(12): p. 1517-1536.
- 425 9. Gaydosik, A.M., et al., Single-cell transcriptome analysis identifies skin-specific
 426 *T-cell responses in systemic sclerosis.* Ann Rheum Dis, 2021. **80**(11): p. 1453427 1460.
- Ryu, C., et al., *Bioactive Plasma Mitochondrial DNA Is Associated With Disease Progression in Scleroderma-Associated Interstitial Lung Disease*. Arthritis &
 Rheumatology, 2020. 72(11): p. 1905-1915.
- 431 11. Ryu, C., et al., *Extracellular Mitochondrial DNA Is Generated by Fibroblasts and*432 *Predicts Death in Idiopathic Pulmonary Fibrosis.* Am J Respir Crit Care Med,
 433 2017. **196**(12): p. 1571-1581.
- Ryu, C., et al., *Bioactive Plasma Mitochondrial DNA Is Associated With Disease Progression in Scleroderma-Associated Interstitial Lung Disease.* Arthritis
 Rheumatol, 2020. **72**(11): p. 1905-1915.
- Bueno, M., et al., *PINK1 attenuates mtDNA release in alveolar epithelial cells and TLR9 mediated profibrotic responses.* PLoS One, 2019. **14**(6): p. e0218003.
- 439 14. Sun, L., et al., *Cyclic GMP-AMP synthase is a cytosolic DNA sensor that*440 *activates the type I interferon pathway.* Science (New York, N.Y.), 2013.
 441 **339**(6121): p. 786-791.
- Hopfner, K.P. and V. Hornung, *Molecular mechanisms and cellular functions of cGAS-STING signalling.* Nat Rev Mol Cell Biol, 2020. 21(9): p. 501-521.

444	16.	Decout, A., et al., The cGAS-STING pathway as a therapeutic target in
445		inflammatory diseases. Nat Rev Immunol, 2021. 21(9): p. 548-569.
446	17.	Arwert, E.N., et al., STING and IRF3 in stromal fibroblasts enable sensing of
447		genomic stress in cancer cells to undermine oncolytic viral therapy. Nat Cell Biol,
448		2020, 22 (7); p. 758-766.
449	18.	Sladitschek-Martens, H.L., et al., YAP/TAZ activity in stromal cells prevents
450	-	ageing by controlling cGAS-STING, Nature, 2022, 607(7920); p. 790-798.
451	19.	Schuliga, M., et al., Self DNA perpetuates IPE lung fibroblast senescence in a
452		cGAS-dependent manner. Clin Sci (Lond). 2020. 134 (7): p. 889-905.
453	20.	Paul. S., et al., Centromere defects, chromosome instability, and cGAS-STING
454		activation in systemic sclerosis. Nat Commun. 2022. 13 (1): p. 7074.
455	21	Ishikawa G et al α 1 Adrenoreceptor antagonism mitigates extracellular
456	2	mitochondrial DNA accumulation in lung fibrosis models and in patients with
457		idionathic nulmonary fibrosis. American Journal of Physiology-Lung Cellular and
458		Molecular Physiology 2023 324 (5): p. 1 639-1 651
459	22	Zhou Y et al Chitinase 3-like 1 suppresses injury and promotes
460	<i>LL</i> .	fibroproliferative responses in Mammalian lung fibrosis. Sci Transl Med. 2014
461		6 (240): p 240ra76
462	23	Lama Let al Development of human cGAS-specific small-molecule inhibitors
463	20.	for repression of dsDNA-triggered interferon expression. Nature
464		Communications 2019 10 (1): p 2261
465	24	Sun H et al Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized
466	۲.	Eibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced
467		Pulmonary Fibrosis Arthritis Rheumatol 2016 68(5): p 1251-61
468	25	Alsafadi H N et al An ex vivo model to induce early fibrosis-like changes in
469	20.	human precision-cut lung slices Am J Physiol I ung Cell Mol Physiol 2017
470		312 (6): p. L896-L902.
471	26.	Fang, F., et al., Toll-like Receptor 9 Signaling Is Augmented in Systemic
472		Sclerosis and Elicits Transforming Growth Factor beta-Dependent Fibroblast
473		Activation, Arthritis Rheumatol, 2016, 68(8); p. 1989-2002,
474	27.	Li, R., et al., cGAS/STING signaling in the regulation of rheumatoid synovial
475		aggression. Ann Transl Med, 2022. 10(8): p. 431.
476	28.	Yu, C.H., et al., TDP-43 Triggers Mitochondrial DNA Release via mPTP to
477		Activate cGAS/STING in ALS. Cell, 2020. 183(3): p. 636-649.e18.
478	29.	An, J., et al., Cutting Edge: Antimalarial Drugs Inhibit IFN-β Production through
479		Blockade of Cyclic GMP-AMP Synthase–DNA Interaction. The Journal of
480		Immunology, 2015, 194 (9); p. 4089-4093.
481	30.	Wang, M., et al., Suramin potently inhibits cGAMP synthase, cGAS, in THP1
482		cells to modulate IFN-B levels. Future Medicinal Chemistry, 2018, 10(11); p.
483		1301-1317.
484	31.	Vincent, J., et al., Small molecule inhibition of cGAS reduces interferon
485		expression in primary macrophages from autoimmune mice. Nature
486		Communications, 2017. 8(1): p. 750.
487	32.	Tan, J., et al., Synthesis and Pharmacological Evaluation of Tetrahvdro-v-
488		carboline Derivatives as Potent Anti-inflammatory Agents Targeting Cyclic GMP-
489		AMP Synthase. Journal of Medicinal Chemistry, 2021. 64(11): p. 7667-7690.

- 33. Deng, Q., et al., Cross-Talk Between Mitochondrial Fusion and the Hippo Pathway in Controlling Cell Proliferation During Drosophila Development.
 Genetics, 2016. 203(4): p. 1777-88.
 34. Nagaraj, R., et al., Control of mitochondrial structure and function by the Yorkie/YAP oncogenic pathway. Genes Dev, 2012. 26(18): p. 2027-37.
 35. Wang, W., et al., Mitochondrial fission triggered by hyperglycemia is mediated by
- 496 ROCK1 activation in podocytes and endothelial cells. Cell Metab, 2012. 15(2): p.
 497 186-200.
- 498 36. Distler, O., et al., *Nintedanib for Systemic Sclerosis–Associated Interstitial Lung*
- 499 *Disease.* New England Journal of Medicine, 2019. **380**(26): p. 2518-2528.

501 **Table 1. Demographic and clinical characteristics of study participants.**

	Healthy controls	SSc without ILD	SSc-ILD
N	12	8	15
Age (mean ± SD)	53.04 ± 14.97	51.89 ± 10.67	60.10 ± 9.70
Gender (n, % female)	6 (50.0%)	8 (100%)	10 (66.7%)
Race			
White (n, %)	9 (75.0%)	6 (75%)	12 (80.0%)
Black (n, %)	3 (25.0%)	1 (12.5%)	2 (13.3%)
Other (n, %)	0 (0%)	1 (12.5%)	1 (6.7%)
Smoking			
Ever (n, %)	2 (16.7%)	3 (37.5%)	7 (44.7%)
Never (n, %)	10 (83.3%)	5 (62.5%)	8 (53.3%)
SSc Subtype			
Diffuse (n, %)	N/A	1 (12.5%)	5 (33.3%)
Limited (n, %)	N/A	7 (87.5%)	10 (66.7%)
Disease Duration (mean ± SD)	N/A	4.50 +/- 2.77	6.44 +/- 3.71
MRSS (median +/- IQR)	N/A	4.5 +/- 6.75	7.0 +/- 3.00
Scl-70 (n, %)	N/A	2 (25%)	7 (46.7%)
Centromere (n, %)	N/A	5 (62.5%)	3 (20.0%)
RNA Pol III (n, %)	N/A	0 (0%)	3 (20.0%)
None (n, %)	N/A	1 (12.5%)	2 (13.3%)
FVC% (mean ± SD)	N/A	90.00 ± 18.98	80.22 ± 19.19
DLCO% (mean ± SD)	N/A	91.14 ± 22.83	64.89 ± 24.80



Figure 1. SSc-ILD lungs show enhanced expression of cGAS and its associated inflammatory mediators. (A) IHC for cGAS showed enhanced detection in the SSc-ILD lung (right) as compared to the normal lung (left). (B) A higher percentage of cGAS positive cells (per high-powered field) was observed in the SSc-ILD lung. BAL fluid samples collected from healthy donors and SSc patients showed that relative to healthy participants, SSc-ILD patients exhibited increased concentrations of (C) IL-6, (D) IL-1 β , (E) TNF- α , (F) MCP-1, (G) IP-10, (H) IFN- α , and (I) IFN- β .



NHLF

SSc-ILD

Figure 2. SSc-ILD lung fibroblasts are enriched for cGAS expression. (A) Violin plot of single cell RNA sequencing analysis (derived from GEO dataset GSE128169) from the lungs of patients with SSc-ILD demonstrating median expression of cGAS-related genes across multiple cell populations, which was highest among immune and endothelial cells. (B) Among stromal cells, fibroblasts (purple) demonstrated enhanced expression of these genes. **(C)** qRT-PCR and **(D)** ELISA measurements of NHLFs and SSc-ILD fibroblasts showed increased transcription and protein expression of cGAS in SSc-ILD fibroblasts. **(E)** IF evaluation of NHLFs (left) and SSc-ILD fibroblasts (right) showed the increased presence of αSMA and cytoplasmic aggregation of cGAS in SSc-ILD fibroblasts (versus the nuclear localization of cGAS in NHLFs). Scale bar = 100 microns.



Figure 3. SSc-ILD fibroblasts express high concentrations of cGAS associated soluble mediators and α SMA. As compared to NHLFs, SSc-ILD fibroblasts expressed high protein levels of (A) IL-6, (B) IL-1 β , (C) TNF- α , (D) MCP-1, (E) IP-10, (F) IFN- α , and (G) IFN- β . Relative to normal cells, SSc-ILD fibroblasts expressed increased α SMA (H) transcripts via RT-qPCR and (I) protein via ELISA.

Figure 4. Small molecule cGAS inhibition mitigates inflammatory fibrotic responses in SSc-ILD fibroblasts. (A) IF staining of naïve (left) and G140 treated (right) SSc-ILD fibroblasts showed reduced detection of both cytoplasmic cGAS aggregates and α SMA in treated cells. Scale bar = 100 microns. These G140cells displayed treated decreased expression of (B) IL-6, (C) IL-1β, (D) TNF-α, (E) MCP-1, (F) IP-10, (G) IFN-α, and (H) IFNβ. Treated cells also displayed a reduction in the (I) transcription and (J) protein expression of αSMA. (K) An MTT assay showed that G140 did not influence the viability of these fibroblasts. Data was normalized to the untreated condition.

medRxiv preprint doi: https://doi.org/10.1101/2024.08.07.24311631; this version posted August 8, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.





Figure 5. A small molecule cGAS inhibitor suppresses inflammatory fibroblast activation induced by TGF β 1 and CpG co-stimulation. (A) IF of NHLFs co-stimulated with TGFB1 and CpG in the absence (left) or presence (right) of G140 showed that treatment diminished the presence of cGAS aggregates in the cytoplasm. Scale bar = 100 microns. Although treatment with G140 did not change levels of (B) IL-6, it attenuated expression of (C) IL-1 β , (D) TNF- α , (E) MCP-1, (F) IP-10, (G) IFN- α , and (H) IFN-β, well mRNA **(I)** as as transcription and (J) protein expression of aSMA. (K) An MTT assay showed that these findings were unrelated to changes in cell viability. Data were normalized to the TGF β 1 + CpG condition.



Figure 6. A small molecule cGAS inhibitor mitigates stiffness-induced fibroblast activation. NHLFs were cultured on tunable hydrogels that approximate the stiffness of the normal (1kPA) and fibrotic (25 kPA) lung. As compared to NHLFs cultured in the untreated 25 kPA condition, those grown on 25 kPA hydrogels treated with G140 exhibited decreased levels of (A) IL-1 β , (B) IP-10, (C) IFN- α , and (D) IFN- β ; expression of (G) MCP-1 remained unchanged. This inhibitor also led to a reduction in the (F) transcription and (G) expression of α SMA. (H) An MTT assay showed that these findings were unrelated to changes in cell viability. Data was normalized to their respective untreated or treated 1 kPA condition.



Figure 7. A small molecule cGAS inhibitor abrogates inflammatory fibrotic responses in human precision cut lung slices. (A) Representative images of Masson's Trichrome staining of human PCLS sections from those subjected to an inflammatory fibrotic cocktail (IFC) in the absence (left) or presence (right) of G140. (B) Collagen quantification via ImageJ software revealed a reduction in collagen content following treatment with G140. Treatment with this inhibitor mitigated expression of (C) IL-6, (D) IL-1 β , (E) TNF- α , (F) MCP-1, (G) IP-10, and (H) IFN- α , and transcription of (I) *ACTA2*. Data were normalized to the IFC condition. (J) Heatmap of bulk RNA sequencing between IFC cultured PCLS in the absence or presence of G140 revealed 126 differentially expressed genes (DEGs). (K) Unbiased pathway enrichment analysis.



Figure 8. A small molecule cGAS inhibitor ameliorates bleomycin induced pulmonary fibrosis. (A) Representative images of Masson's Trichrome staining of lung sections from bleomycin challenged mice in the absence (left) or presence (right) of G140. Collagen quantification via (B) ImageJ software and (C) Sircol assay revealed a reduction in collagen content following treatment with G140. Bleomycin exposed mice treated with G140 displayed reduced BAL concentrations of (D) IL-6, (E) TNF- α , (F) IP-10, (G) IFN- α , and (H) IFN- β , while levels of (H) IL-1 β and (J) MCP-1 remained unchanged.